Skip to content
DataLookout
Menu

Myelofibrosis clinical trials

Get alerts when Myelofibrosis trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-08

What changed in the last 30 days

21 trials changed in the last 30 days: 1 stopped, 9 with notable changes, 11 with minor changes only.

  1. Minor: ELRISE MF · Elritercept to Placebo · Myelofibrosis and Anemia Who Are Taking Ruxolitinib Trial sites expanded: 195 → 214 locations TakedaPhase 3 NCT07623161
  2. Stopped: Hu8F4 · Advanced Hematologic Malignancies Trial terminated M.D. Anderson Cancer CenterPhase 1 NCT02530034
  3. Minor: MANIFEST-3 · Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) Trial sites expanded: 159 → 163 locations Novartis PharmaceuticalsPhase 3 NCT07357727
  4. Minor: ODYSSEY · Momelotinib in Combination With Luspatercept · Transfusion Dependent Myelofibrosis Study completion pushed from Mar 17, 2028 to Jan 31, 2029 GlaxoSmithKlinePhase 2 NCT06517875
  5. Notable: PHEMOP · Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes Primary completion pushed from Nov 19, 2026 to May 29, 2027 University Hospital, AngersNot applicable NCT06361641
  6. Minor: PRT12396 · Select Myeloproliferative Neoplasms Trial sites expanded: 18 → 22 locations Prelude Therapeutics IncorporatedPhase 1 NCT07469891
  7. Notable: JAK-PeriMF · Use of Gecacitinib · Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period Following Allogeneic Hematopoietic Stem Cell Transplantation Recruitment opened Ruijin HospitalPhase 1/2 NCT07883382
  8. Notable: Extended Access of Momelotinib · Myelofibrosis Primary endpoint(s) modified GlaxoSmithKlinePhase 2 NCT03441113
  9. Notable: Selinexor and Pacritinib in JAK Inhibitor-naïve MF · Cytopenias Recruitment opened John MascarenhasPhase 2 NCT07447817
  10. Minor: CLARITY-101 · DMR-001 · CALR-mutant Myeloproliferative Neoplasms Trial sites expanded: 4 → 36 locations Damora TherapeuticsPhase 1 NCT07849231
  11. Notable: Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow Primary completion pushed from Jun 2026 to Jun 2027 University of California, IrvinePhase 1/2 NCT07281781
  12. Notable: Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Primary and study completion dates pushed to Feb 14, 2030 City of Hope Medical CenterPhase 1 NCT07020533
  13. Notable: CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors · CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Primary completion moved earlier from Jan 1, 2028 to Jan 1, 2027 City of Hope Medical CenterPhase 2 NCT06059391
  14. Minor: DISC-0974 (RALLY-MF) · Myelofibrosis or Myelodysplastic Syndrome and Anemia Trial sites expanded: 32 → 35 locations Disc Medicine, IncPhase 1/2 NCT05320198
  15. Notable: Therapeutic RSK1 Targeting in Myeloid Malignancies Enrollment increased: 18 → 30 participants Washington University School of MedicinePhase 1 NCT07379125
  16. Notable: TREG108 · Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs Primary completion pushed from Apr 30, 2026 to Apr 30, 2027 Cellenkos, Inc.Phase 1 NCT05423691
  17. Minor: PACER · Pacritinib Effectiveness in Real-world Settings Primary and study completion pushed from Jan 27, 2027 to Mar 10, 2027 Swedish Orphan BiovitrumNot specified NCT07774455
  18. Minor: RopeRux · Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis Start date changed from estimate of Oct 2026 to Aug 21, 2026 University of UtahPhase 1 NCT07521046
  19. Minor: Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis Changed Registry marked status Unknown (sponsor has not verified the record since Feb 2023); last known: Recruiting National Taiwan University HospitalPhase 2 NCT05731245
  20. Minor: ATIOM · AlloHCT With PegINFa for Myelofibrosis Primary completion pushed from Aug 2026 to Jan 2027 University of UtahPhase 1 NCT05535764
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-11-02 NCT07909733 Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After… University of Wisconsin, Madison new Phase 1
2026-10-20 NCT07883382 An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and… Ruijin Hospital new Phase 1/2
2026-10-07 NCT07863466 MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients… Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico new

Active trials by phase

Early Phase 1
3
Phase 1
41
Phase 1/2
17
Phase 2
42
Phase 2/3
1
Phase 3
13
Phase 4
2
Not charted: 41 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when Myelofibrosis trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free